Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Diabetes mellitus does not alter mortality or hospitalisation risk in patients with newly diagnosed heart failure with preserved ejection fraction: Time to rethink pathophysiological models of disease progression

Title: Diabetes mellitus does not alter mortality or hospitalisation risk in patients with newly diagnosed heart failure with preserved ejection fraction: Time to rethink pathophysiological models of disease progression
Authors: Gierula, John; Straw, Sam; Cole, Charlotte A; Lowry, Judith E; Paton, Maria F; McGinlay, Melanie; Witte, Klaus K; Grant, Peter J; Wheatcroft, Stephen B; Drozd, Michael; Slater, Thomas A; Cubbon, Richard M; Kearney, Mark T
Contributors: British Heart Foundation
Source: Diabetes and Vascular Disease Research ; volume 21, issue 2 ; ISSN 1479-1641 1752-8984
Publisher Information: SAGE Publications
Publication Year: 2024
Description: Introduction Type 2 diabetes is a common and adverse prognostic co-morbidity for patients with heart failure with reduced ejection fraction (HFrEF). The effect of diabetes on long-term outcomes for heart failure with preserved ejection fraction (HFpEF) is less established. Methods Prospective cohort study of patients referred to a regional HF clinic with newly diagnosed with HFrEF and HFpEF according to the 2016 European Society of Cardiology guidelines. The association between diabetes, all-cause mortality and hospitalisation was quantified using Kaplan-Meier or Cox regression analysis. Results Between 1st May 2012 and 1st May 2013, of 960 unselected consecutive patients referred with suspected HF, 464 and 314 patients met the criteria for HFpEF and HFrEF respectively. Within HFpEF and HFrEF groups, patients with diabetes were more frequently male and in both groups patients with diabetes were more likely to be treated with β-adrenoceptor antagonists and angiotensin converting enzyme inhibitors. After adjustment for age, sex, medical therapy and co-morbidities, diabetes was associated with increased mortality in individuals with HFrEF (HR 1.46 95% CI: 1.05–2.02; p = .023), but not in those with HFpEF (HR 1.26 95% CI 0.92–1.72; p = .146). Conclusion In unselected patients with newly diagnosed HF, diabetes is not an adverse prognostic marker in patients with HFpEF, but is in HFrEF.
Document Type: article in journal/newspaper
Language: English
DOI: 10.1177/14791641231224241
Availability: https://doi.org/10.1177/14791641231224241; https://journals.sagepub.com/doi/pdf/10.1177/14791641231224241; https://journals.sagepub.com/doi/full-xml/10.1177/14791641231224241
Rights: https://creativecommons.org/licenses/by/4.0/
Accession Number: edsbas.D4890C2F
Database: BASE